InflaRx N.V. Launches At-The-Market Share Offering
Ticker: IFRX · Form: 6-K · Filed: Jun 28, 2024 · CIK: 1708688
Sentiment: neutral
Topics: at-the-market offering, capital raise, equity
TL;DR
InflaRx is selling shares via an ATM offering with Leerink Partners.
AI Summary
On June 28, 2024, InflaRx N.V. entered into a Sales Agreement with Leerink Partners LLC to conduct an "at-the-market" offering of its ordinary shares. This agreement allows the company to sell shares opportunistically to raise capital.
Why It Matters
This filing indicates InflaRx N.V. is raising capital through share sales, which could fund ongoing research and development or other corporate initiatives.
Risk Assessment
Risk Level: medium — At-the-market offerings can dilute existing shareholders' ownership and may signal a need for capital, but they also provide flexibility for fundraising.
Key Players & Entities
- InflaRx N.V. (company) — Registrant
- Leerink Partners LLC (company) — Sales Agent
- June 28, 2024 (date) — Date of Sales Agreement
FAQ
What is the purpose of the Sales Agreement entered into by InflaRx N.V.?
The Sales Agreement with Leerink Partners LLC provides for the sale of the Company's ordinary shares pursuant to an 'at-the-market' offering.
Who is the counterparty to the Sales Agreement with InflaRx N.V.?
The Sales Agreement was entered into with Leerink Partners LLC.
When was the Sales Agreement between InflaRx N.V. and Leerink Partners LLC executed?
The Sales Agreement was entered into on June 28, 2024.
What type of offering is being conducted under the Sales Agreement?
The offering is an 'at-the-market' offering of the Company's ordinary shares.
Under which SEC form is this report filed?
This report is filed as a Form 6-K.
Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 7.4 · Accepted 2024-06-28 16:55:32
Filing Documents
- ny20030768x3_6k.htm (6-K) — 12KB
- ny20030768x3_ex99-1.htm (EX-99.1) — 264KB
- 0001140361-24-031784.txt ( ) — 277KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: June 28, 2024 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer